Pharmacokinetic considerations of antidepressant use in the elderly

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 20, 1999, Pages 38-44

  DeVane, C Lindsay ^a   Pollock, Bruce G ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; AURALGAN; CITALOPRAM; CLOMIPRAMINE; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; GABAPENTIN; LORAZEPAM; MIRTAZAPINE; NEFAZODONE; NIFEDIPINE; NORTRIPTYLINE; OXAZEPAM; PAROXETINE; PERPHENAZINE; PHENAZONE; PREDNISOLONE; RISPERIDONE; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE; VERAPAMIL; WARFARIN;

AGING; ARTICLE; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; GERIATRIC CARE; HUMAN; KIDNEY FUNCTION; LIVER METABOLISM; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOTRANSFORMATION; BUPROPION; CREATININE; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; LIVER; MALE; MIDDLE AGED; TRIAZOLES;

EID: 0032836203     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. O'Mahony MS, Woodhouse KW. Age, environmental factors and drug metabolism. Pharmacol Ther 1994;61:279-287
2. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-283
3. Schmucker DL, Woodhouse KW, Wang RK, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990;48:365-374
4. Loi CM, Vestal RE. Drug metabolism in the elderly. Pharmacol Ther 1988; 36:131-149
5. Pollock BG. Gender differences in psychotropic drug metabolism. Psychopharmacol Bull 1997;33:235-241
6. Greenblatt DJ, Allen MD, Harmatz JS, et al. Diazepam disposition determinants. Clin Pharmacol Ther 1980;27:301-312
7. Verbeeck RK, Cardinal JA, Wallace SM. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 1984;27:91-97
8. Pollock BG, Perel JM, Altieri LP, et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992;28: 163-168
9. May DG, Porter J, Wilkinson GR, et al. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 1994;55:492-500
10. Hardy BG, Shulman KI, Mackenzie SE, et al. Pharmacokinetics of lithium in the elderly. J Clin Psychopharmacol 1987;7:153-158
11. DeVane CL. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 1999;19:443-466
12. Vestal RE, Norris AH, Tobin JD, et al. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin Pharmacol Ther 1975; 18:425-432
13. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997;61:331-339
14. Loi CM, Parker BM, Cusack BJ, et al. Aging and drug interactions, III: individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther 1997;80:627-637
15. Wynne HA, Kamali F, Edwards C, et al. Effect of ageing upon warfarin dose requirements: a longitudinal study. Age Ageing 1996;25:429-431
16. Kunik ME, Pollock BG, Peril JM, et al. Clomipramine in the elderly: tolerance and plasma levels. J Geriatr Psychiatry Neurol 1994;7:139-143
17. Foglia JP, Pollock BG, Kirshner MA, et al. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull 1997;33:109-112
18. Robertson DR, Waller DG, Renwick AG, et al. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1998;25:297-305
19. Miglioli PA, Pivetta P, Strazzabosco M, et al. Effect of age on single- and multiple-dose pharmacokinetics of erythromycin. Eur J Clin Pharmacol 1990;39:161-164
20. Hunt CM, Westerkam WR, Stave GM, et al. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. Mech Ageing Dev 1992;64:189-199
21. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423
22. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird L, Molinoff PB, et al, eds. Goodman and Gilman's Pharmacologic Basis of Therapeutics. New York, NY: McGraw-Hill; 1996:14
23. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21
24. Pollock BG, Mulsant BH, Sweet R, et al. An open pilot study of citalopram for behavioral disturbances of dementia: plasma levels and real-time observations. Am J Geriatr Psychiatry 1997;5:70-78
25. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harv Rev Psychiatry 1994;2:204-213
26. Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996;16:19-25
27. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997;32(1, suppl):22-30
28. Norman TR. Pharmacokinetic aspects of antidepressant treatment in the elderly. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:329-344
29. Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995;35:876-884
30. Barbhaiya RH, Shukla UA, Green DS. Single dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Eur J Clin Pharmacol 1995;49:221-228
31. Klamerus KJ, Maloney KA, Rudolph R, et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992;32:716-724
32. Remeron (mirtazapine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1999:2147-2149
33. Fredericson Overo K, Toft B, Christophersen L, et al. Kinetics of citalopram in elderly patients. Psychopharmacology (Berl) 1985;86:253-257
34. Prozac (fluoxetine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1999:924-928
35. Bergstrom RF, Farid KZ, McClurg JE, et al. The pharmacokinetics of fluoxetine in elderly subjects. Presented at the 2nd World Conference on Clinical Pharmacologic Therapies: Drugs and the Elderly; Aug 4, 1983; Washington, DC
36. DeVries MH, van Harten J, van Bemmel P, et al. Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharm Drug Dispos 1993;14:291-296
37. Hebenstreit GF, Fellerer K, Zochling R, et al. A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiatr Scand 1989;80(suppl 350):81-84
38. Ghose K. The pharmacokinetics of paroxetine in elderly depressed patients. Acta Psychiatr Scand 1989;80(suppl 350):87-88
39. Bayer AJ, Roberts NA, Allen EA, et al. The pharmacokinetics of paroxetine in the elderly. Acta Psychiatr Scand 1989;80(suppl 350):85-86
40. Lundmark J, Scheel-Thomsen I, Fjord-Larsen T, et al. Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand 1989;80(suppl 350):76-80
41. Laizure SC, DeVane CL, Stewart JT, et al. Pharmacokinetics of bupropion and its major basic metabolites in normal volunteers. Clin Pharmacol Ther 1985;38:586-589
42. Effexor (venlafaxine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1999:3291-3298
43. Luvox (fluvoxamine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1999:3121-3124
44. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989;80 (suppl 350):60-75
45. Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-295